Wegovy, Ozempic and other new GLP-1 agonist drugs can control diabetes, melt pounds away and, possibly, perform other medical miracles, but it's not good for employers' financial wellness.
Employers told the Business Group on Health that they believe the popularity of high-cost GLP-1 agonists is one of the main reasons health care cost increases are picking up.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.